Skip to main content
SpringerLink
Log in

When treating chronic pelvic pain in women, consider peripheral and central contributors

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The management of chronic pelvic pain (CPP) in women requires a multimodal approach, as such pain is often generated both centrally and peripherally. The role of neurobiological and neuropsychological factors in contributing to CPP should be considered. The comprehensive management of CPP in women includes the use of pharmacological options (e.g. analgesics, hormonal suppression, anaesthetics, antidepressants, membrane stabilizers and anxiolytics) and non-pharmacological interventions (pelvic floor physical therapy, cognitive behavioural therapy, lifestyle modifications).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Howard FM. ACOG practice bulletin no. 51: chronic pelvic pain. Obstet Gynecol. 2004;103:589–605.

    Article  Google Scholar 

  2. Carey ET, Till SR, As-Sanie S. Pharmacological management of chronic pelvic pain in women. Drugs. 2017;77(3):285–301.

    Article  CAS  PubMed  Google Scholar 

  3. Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2:CD001751.

    Google Scholar 

  4. Garcia-Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthr Rheum. 1997;26:16–20.

    Article  CAS  Google Scholar 

  5. Makin AJ, Williams R. Acetaminophen-induced hepatotoxicity: predisposing factors and treatments. Adv Intern Med. 1997;42:453–83.

    CAS  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention. Public Health Service, U.S. Department of Health and Human Services. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother. 2016;30(2):138–40.

    Article  Google Scholar 

  7. Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011;118:691–705.

    Article  CAS  PubMed  Google Scholar 

  8. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010;12:CD008475.

    Google Scholar 

  9. Telimaa S, Puolakka J, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. 1987;1:13–23.

    Article  CAS  PubMed  Google Scholar 

  10. Foster DC, Kotok MB, Huang L-S, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010;116:583–93.

    Article  CAS  PubMed  Google Scholar 

  11. Labat JJ, Riant T, Lassaux A, et al. Adding corticosteroids to the pudendal nerve block for pudendal neuralgia: a randomised, double-blind, controlled trial. BJOG. 2016;124:251–60.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Scott NA, Guo B, Barton PM, et al. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Med. 2009;10:54–69.

    Article  PubMed  Google Scholar 

  13. Sator-Katzenschlager SM, Scharbert G, Kress HG, et al. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr. 2005;117:761–8.

    Article  CAS  PubMed  Google Scholar 

  14. Moldofsky H, Harris HW, Archambault WT, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;38:2653–63.

    Article  CAS  PubMed  Google Scholar 

  15. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975–85.

    CAS  PubMed  Google Scholar 

  16. Lewis SC, Bhattacharya S, Wu O, et al. Gabapentin for the management of chronic pelvic pain in women (GaPP1): a pilot randomised controlled trial. PLoS One. 2016;11:e0153037.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Muehlbacher M, Nickel MK, Kettler C, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2006;22:526–31.

    Article  PubMed  Google Scholar 

  18. Carrico DJ, Peters KM. Vaginal diazepam use with urogenital pain/pelvic floor dysfunction: serum diazepam levels and efficacy data. Urol Nurs. 2011;31:279–84.

    PubMed  Google Scholar 

  19. Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19:160–7.

    Article  PubMed  Google Scholar 

  21. Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21:363–71.

    Article  PubMed  Google Scholar 

  22. Turini D, Beneforti P, Spinelli M, et al. Heat/burning sensation induced by topical application of capsaicin on perineal cutaneous area: new approach in diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome? Urology. 2006;67:910–3.

    Article  PubMed  Google Scholar 

  23. Rocha MG, e Silva JC, da Silva AR, et al. TRPV1 expression on peritoneal endometriosis foci is associated with chronic pelvic pain. Reprod Sci. 2011;18:511–5.

    Article  CAS  PubMed  Google Scholar 

  24. Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108(4):915–23.

    Article  PubMed  Google Scholar 

  25. Jarvis SK, Abbott JA, Lenart MB, et al. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44(1):46–50.

    Article  PubMed  Google Scholar 

  26. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33:451–9.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Younger J, Noor N, McCue R, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthr Rheum. 2013;65:529–38.

    Article  CAS  Google Scholar 

  28. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Walitt B, Klose P, Fitzcharles MA, et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694.

    PubMed  Google Scholar 

  30. Hochberg MC, Tive LA, Abramson SB, et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthr Rheum. 2016;68:382–91.

    Article  CAS  Google Scholar 

  31. Nickel JC, Mills IW, Crook TJ, et al. Tanezumab reduces pain in women with interstitial cystitis/bladder pain syndrome and patients with nonurological associated somatic syndromes. J Urol. 2016;195:942–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Drugs 2017;77(3):285–301 [2] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest. The preparation of this review was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. When treating chronic pelvic pain in women, consider peripheral and central contributors. Drugs Ther Perspect 33, 418–423 (2017). https://doi.org/10.1007/s40267-017-0429-3

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-017-0429-3

    Search

    Navigation